Related GDX Technical Alert: Gold Futures Higher Technical Alert: Gold Futures Three Day Winning Streak In Jeopardy GDX: Institutions Were Buying On Friday (Seeking Alpha)
Related GDXJ Gold's Selloff Accelerates, But Still One Of 2016's Best Performers David Bartosiak's Market Vectors Junior....More>>>
GrubHub, Inc. (NYSE:GRUB) is an over-hyped growth stock whose growth prospects are misunderstood by the market. Despite big growth as a first-mover to the large online food and delivery service market, GRUB’s business model is defenseless despite its perceived “network effect.” GRUB’s projected growth runway will be eaten up by competing products from goliaths:....More>>>
Cultivating Marijuana or Cannabis as the next multibillion dollar industryhas garnered considerable attention, but small cap Algae Dynamics Corp (OTCQB: ADYNF) is commercializing contaminant-free algae. On the surface, that may not sound so exciting as algae isusuallyconsideredan unwanted side effect ofstagnant water or a toxin (e.g. an algae bloom)that damages some forms of sea life.
Betting on a stronger dollar has been one of the most punishing consensus trades of 2017.
But instead of backing away from it, the Wall Street investment banks that recommended this trade to their clients are advising them to hold the position, arguing that an aggressive Fed and President Donald Trumps looming tax-reform shakeup will soon trigger a turnaround.
April 18, 2017: Here are four stocks trading with relatively heavy volume among 85 equities making new 52-week lows in Tuesday’s session. On the NYSE, decliners led advancers by about 8 to 7 and on the Nasdaq advancers led decliners by about 7 to 6.
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing....More>>>
At 4 p.m. ET this afternoon, U.S. President Barack Obama will reveal the eight individuals he’s tasked with serving on his Puerto Rico oversight board. These folks will be charged with restructuring the commonwealth’s massive $70 billion debt burden.
To be clear: This board is not tasked withdoling out another bailout placed at the feet of American taxpayers. It’s more....More>>>
Morgan Stanley’s David Risinger and team give their thoughts on one of the most pressing questions for investors in shares of Valeant Pharmaceuticals International (VRX)–when will it be safe to invest? The answer is unclear:
When will it be safe to go back into the water? Over the last few months, it seems every time investors thought that there....More>>>
Our Long Idea reports aim to identify those firms that the market has overlooked and that, when analyzed beyond standard metrics, are significantly undervalued. These hidden gems provide excellent upside potential to any portfolio, with little downside risk.
In addition to individual Long Ideas, we provide Model Portfolios that provide well-screened lists of companies based on specific criteria....More>>>
Conventional wisdom suggests rising rates are bad for real estate investment trusts. In fact, that’s not always true. REITs have historically done well when the cost of money is increasing, asserts Keith Fitz-Gerald, editor of Total Wealth.
Between 1994 and 2013, for example, there were nine time periods when interest rates rose by more than 1% (or 100 basis points in trader speak)....More>>>
Investor confusion about Apple (NYSE: AAPL) choosing Finisar (NYSE: FNSR) to provide VCSEL sensors in Apple iPhones has caused FNSR to fall recently and this is providing an excellent entry point into the stock.
Based on DCF analysis, we anticipate a Finisar share price of $29 in the seco
Financial Engines (FNGN) was co-founded in 1996 by William F. Sharpe, a winner of the 1990 Nobel Prize in Economic Sciences for his work on the theory of financial economics. Sharpe studied how prices of financial assets are determined, and the link between risk and return. Financial Engines wen
Cerus Corporation (CERS) is a $271 million market cap company focused on blood transfusion products. The company has viable products and anticipates it's increasing sales of platelet products is removing some previous sales ramp uncertainty. By expanding its supply agreement with the French Natio